Table 2.

Genotyping frequencies for HER-2 in cases and controls and their association with risk of overall lung cancer

	Genotype	Case (n = 407)	Control (n = 407)	asOR (95% CI)a	p-value
-3444 C>T	CC	141	140	1
	CT	201	205	0.97 (0.72 – 1.32)	0.86
	TT	65	62	1.04 (0.68 – 1.58)	0.85
	CT+TT	266	267	0.99 (0.74 – 1.32)	0.94
	CC+CT	342	345	1
	TT	65	62	1.06 (0.72 – 1.55)	0.77
-1985 G>T	GG	144	140	1
	GT	196	205	0.93 (0.69 – 1.26)	0.64
	TT	67	62	1.05 (0.69 – 1.59)	0.82
	GT+TT	263	267	0.96 (0.72, 1.28)	0.77
	GG+GT	340	345	1
	TT	67	62	1.10 (0.75-1.60)	0.63
I655V A>G	AA	304	300	1
	AG	97	97	0.99 (0.71 – 1.36)	0.93
	GG	5	6	0.82 (0.25 – 2.72)	0.75
	AG+GG	102	103	0.98 (0.71 – 1.34)	0.88
	AA+AG	401	397	1
	GG	5	6	0.83 (0.25 – 2.73)	0.75
P1170A C>G	CC	144	137	1
	CG	199	206	0.92 (0.68 – 1.25)	0.59
	GG	64	64	0.95 (0.63 – 1.45)	0.82
	CG+GG	263	270	0.93 (0.69 – 1.24)	0.61
	CC+CG	343	343	1
	GG	64	64	1.00 (0.69 – 1.46)	1

OR, odds ratio; CI, confidence interval.

^aasOR are adjusted for age and gender.